Revance Therapeutics Inc
(FRA:RTI)
€
3.5
-0.08 (-2.23%)
Market Cap: 358.58 Mil
Enterprise Value: 642.04 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 68/100 Revance Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 10, 2020 / 03:15PM GMT
Release Date Price:
€21
(-11.76%)
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst
© -
Hello everyone, my name is Evan Seigerman. I'm the senior large cap bio pharma analyst here at Credit Suisse. And welcome to day 2 of the virtual healthcare -- Virtual Global Healthcare Conference. We're looking very much forward to seeing everyone in person next year. But with me today for the 10:15 session is Revance Therapeutics. And from Revance, I have Tobin Schilke, CFO.
Did I get your pronunciation correct?
Tobin C. Schilke
Revance Therapeutics, Inc. - CFO & Principal Accounting Officer
You nailed it, Evan.
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst
© -
Excellent. And then one thing, so participants on the line, if you want to ask a question to Tobin, please just send me an email at [email protected]. I'm sure many of you have my e-mail address, and I can ask on your behalf
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot